Stada Generics Takes A Hit Even As Firm Steals A March On Rivals
Group’s Sales ‘Better Than The Average For The Top-Five Suppliers’
Executive Summary
Stada saw a small drop in both sales and profitability for its Generics division, but insisted the firm’s “strong position in generics,” alongside its leading position in consumer healthcare and growing specialty offering, “put the group on a sustainable growth course.”
You may also be interested in...
Stada And NTC Ally On MENA Ophthalmic Brands
Stada has struck a deal to partner with Italy’s NTC to market a portfolio of ophthalmic brands in the MENA region. At the same time, the German generics giant has agreed a distribution deal for the Czech Republic with Latvia’s Kalceks.
Stada Expands Portfolio In US And Nordics As First-Half Sales Rise
Stada reported Branded Products sales up 9% in the first half as it secured two additions to its portfolio, with a US dietary supplement brand and Nordic herbal analgesic.
Stada Partners With Calliditas On Novel Budesonide Formulation
Stada has struck a licensing and commercialization deal with Calliditas worth more than $100m to partner on a novel oral formulation of budesonide to treat Immunoglobulin A Nephropathy in Europe.